A penta-decapeptide comprised of 15 amino acids, is derived from the body protection compound (BPC) initially discovered in human gastric juice. Through animal studies, it has demonstrated the capacity to expedite the healing process for various types of injuries, including those affecting muscles, tendons, and ligaments. Furthermore, BPC 157 exhibits protective properties for organs and contributes to the prevention of gastric ulcers. This peptide exerts systemic effects within the digestive tract, addressing issues like leaky gut, irritable bowel syndrome (IBS), gastrointestinal cramps, and Crohn’s disease. Additionally, BPC-157 possesses analgesic qualities and has been shown to enhance the healing of skin burns by promoting increased blood circulation in damaged tissues. Notably, it accelerates the formation of reticulin and collagen, fosters angiogenesis, and stimulates the infiltration of macrophages and fibroblasts, making it a promising therapeutic option for managing wound healing.

Structure

Molecular composition and structural details of BPC-157

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molecular Formula: C₆₂H₉₈N₁₅O₂₂

Molecular Weight: 1419.556 g mol−11419.556 gmol−1

PubChem CID: 108101

Short for Body Protection Compound-157, is a derivative of body protection compound (BPC). BPC is a protein found naturally in the human digestive tract. It plays a significant role in protecting the lining of the gastrointestinal tract from damage, promoting healing, and encouraging blood vessel growth. Synthetic BPC-157, a pentadecapeptide comprising 15 amino acids isolated from the much larger BPC protein, has been found to retain many of the healing properties of its parent molecule. In particular, BPC-157 has been shown to have effects on:

• Wound healing
• Blood vessel growth
• The coagulation cascade
• Nitric oxide generation
• Immune system function
• Gene expression
• Hormone regulation (particularly in the gastrointestinal nervous system)

Research:

BPC-157 and Wound Healing

Scientific studies on BPC-157 and wound healing mechanism

Naturally plays a crucial role in maintaining the integrity of the mucosal barrier within the gastrointestinal (GI) tract, safeguarding underlying tissues from the corrosive effects of gastric acid, bile, and other substances necessary for digesting and absorbing nutrients. A significant aspect of this function involves the recruitment of fibroblasts. BPC-157 has been observed to exert a dose-dependent influence on the proliferation and migration of fibroblasts, both in culture and in vivo[1]. Fibroblasts hold a pivotal role in the wound healing process as they are responsible for depositing essential extracellular matrix proteins like collagen, fibrin, elastin, and others.

What’s even more intriguing is that Adipotide treatment and the ensuing fat loss didn’t solely affect physical transformation but also played a pivotal role in altering eating habits. Monkeys that shed weight through the use of Adipotide displayed a concurrent reduction in their food consumption, hinting at the intricate interplay between this revolutionary compound and an individual’s dietary choices.

Vascular Growth and Collateralization

BPC-157's role in promoting blood vessel growth and angiogenesis

Demonstrates remarkable angiogenic properties by significant boosting the proliferation and development of endothelial cells, the cells lining blood vessels[1]–[3]. Rat studies have shown that this peptide notably accelerates the growth of collateral blood vessels in cases of ischemia[4]. While these effects have been predominantly observed in the gastrointestinal (GI) tract, there is promising evidence indicating similar advantages in cardiovascular, neurological, and muscular tissues. This suggests that BPC-157 could serve as a therapeutic option for conditions like stroke and heart attack, while also offering insights into the mechanisms behind healing after ischemic injuries[5], [6]

Studies conducted with chicken embryos suggest that BPC-157’s promotion of vascular growth may, in part, occur through the stimulation of VEGFR2, a cell surface receptor that plays a vital role in the nitric oxide signaling pathway[4], [7], [8]. VEGFR2 is believed to be a key factor in the growth, proliferation, and longevity of endothelial cells.

In cell culture experiments, BPC-157 has shown the ability to promote vascular “running.” This phenomenon involves the growth of blood vessels toward an injured area or around a vascular blockage to restore blood flow to distant tissues and safeguard cellular function[9]. This specific characteristic of BPC-157 holds the potential to pave the way for an effective oral treatment for slowly developing arterial obstructions, such as those seen in atherosclerotic heart disease. This research area has the potential to reduce the necessity for surgical procedures like stenting and coronary artery bypass grafting in the future.

BPC-157 and Tendon Healing

Effects on connective tissue repair and tendon healing mechanisms

Positive effects in animal models of tendon, ligament, bone, and other connective tissue injuries are attributed to its roles in fibroblast recruitment and blood vessel growth. Tendon and ligament injuries are known for their slow healing due to limited blood supply in these tissues. This restricted blood flow hinders the arrival of fibroblasts and other cells crucial for wound healing, ultimately limiting the overall repair process. In both laboratory and animal studies involving rat tendons, BPC-157 has been found to enhance collateralization and increase fibroblast density when dealing with injuries to tendons, ligaments, and bones. These findings suggest that BPC-157 is more effective than hormones like bFGF, EFG, and VGF in promoting healing in these tissues[10].

Experiments utilizing FITC-phalloidin staining have revealed that BPC-157 strongly stimulates F-actin formation in fibroblasts[11]. F-actin is vital for cell structure and function, particularly in cell migration. Western blot analysis has indicated that BPC-157 elevates the phosphorylation levels of paxillin and FAK proteins, both of which play crucial roles in the cell migration pathway[12].

Antioxidant Properties

BPC-157's role in combating oxidative stress and free radicals

Studies conducted on rats have demonstrated that BPC-157 possesses the capability to counteract specific oxidative stress markers such as nitric oxide and malondialdehyde (MDA)[3]. This attribute renders BPC-157 a potent antioxidant, a quality that is reinforced by research revealing its ability to decrease the generation of reactive oxygen species within the gastrointestinal tract. Furthermore, research exploring the potential use of modified lactococcus lactis bacteria as a delivery method for BPC-157 in the gastrointestinal system has indicated a significant increase in peptide levels within cell culture[13].

BPC-157 and Drug Side Effects

Protective effects against pharmaceutical side effects

In many cases, the primary obstacle to the long-term use of medical pharmaceuticals is the occurrence of side effects. For example, NSAIDs such as ibuprofen are limited in their long-term usage due to their propensity to elevate the risk of gastric bleeding and heart attacks. Finding a way to mitigate side effects while preserving the desired therapeutic effects is a significant goal in contemporary medical research, as it could enhance the therapeutic advantages of numerous drugs. BPC-157 has exhibited the ability to counteract the side effects associated with NSAIDs, medications used in psychiatric conditions, and several heart medications.

While it is expected that BPC-157 can alleviate many of the gastrointestinal side effects associated with certain drugs, it’s noteworthy that the peptide can also offer protection against side effects in various other organs, including the brain and heart. Studies in rats, for instance, have demonstrated that BPC-157 has the potential to shield against QTc prolongation in the heart, a condition that can lead to severe and even life-threatening arrhythmias. QTc prolongation is typically induced by medications used to treat diabetes, schizophrenia, and other psychiatric disorders. Additionally, BPC-157 has been found to prevent other adverse effects caused by psychiatric medications, including significant side effects such as catalepsy and somatosensory disturbances. This protective effect may pave the way for more effective treatment of psychiatric conditions, which are often challenging to manage due to patients discontinuing their medications due to severe side effects.

BPC-157 and Bees

Research on BPC-157's effects on honey bee health and colony collapse disorder

Colony collapse disorder (CCD) is a phenomenon in which entire colonies of honey bees experience rapid and devastating population declines. While the exact causes of CCD remain unclear, one contributing factor appears to be an infection in honey bee guts caused by the fungus Nosema ceranae. Researchers have conducted experiments where they supplemented the diet of honey bees with BPC-157. These studies have demonstrated a reduction in the damage caused by the fungus in the gastrointestinal tracts of honey bees and, as a result, an increase in hive survival rates. Importantly, these trials were conducted in natural field settings, marking a significant milestone as it provides a viable oral treatment to mitigate the impact of CCD on honey bee populations, which are crucial pollinators for many food crops.

Future Research

Ongoing investigations and potential applications of BPC-157

Currently the subject of active investigation in various cell culture and animal models. This peptide shows significant potential, not only as a therapeutic agent for enhancing wound healing and regulating vascular growth but also as a valuable tool for conducting research to gain a better understanding of these processes and their control mechanisms. Studies involving BPC-157 have the potential to provide valuable insights into angiogenesis, a process critical for wound healing and with widespread implications in growth, cancer development, and embryogenesis. It’s worth noting that BPC-157 demonstrates minimal side effects, has moderate oral and excellent subcutaneous bioavailability in mice. However, it’s important to emphasize that the dosage per kilogram in mice does not directly translate to humans. BPC-157 available for purchase at Spartan Research is intended solely for educational and scientific research purposes and is not intended for human consumption. Only licensed researchers should consider acquiring BPC-157 for their studies.

 

 

Structure

Molecular composition and structural details of Modified GRF 1-29

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molar Mass: 3368.7 g/mol

Synonyms: Mod GRF 1-29, CJC-1295 no DAC

Introduction

Overview of Modified GRF 1-29 and its properties:

Modified GRF (Mod GRF) 1-29, also known as CJC-1295 without DAC, is a truncated peptide analogue of growth hormone-releasing hormone (GHRH). Initially developed in the 1980s, Mod GRF has shown potential in enhancing muscle repair and growth, accelerating wound healing, strengthening bones, improving fat metabolism, and boosting overall metabolism. It also offers potential benefits in regulating blood sugar levels and supporting the immune system.

MOD-GRF 1-29 is described as a growth hormone–releasing hormone (GHRH) analogue and does not contain DAC (drug affinity complex). It was developed to help overcome the short half-life of natural GHRH, supporting a longer duration of action in stimulating growth hormone.

Research Notes (Mechanism/Context Summary):
• MOD-GRF 1-29 binds to GHRH receptors in the pituitary gland, promoting GH production.• It’s described as helping maintain the natural rhythmic release of GH (supporting balanced physiology), and may influence downstream hormones like IGF-1.
• Combining MOD-GRF 1-29 with GHRPs is discussed as enhancing GH release by inhibiting somatostatin-related suppression, supporting more effective GH output.
• Additional research discussion includes potential roles in gut/inflammatory contexts and possible cardioprotective effects.

 

 

Introduction:

Extending GHRH activity with DAC technology.  Classical GHRH analogues mimic the hormone’s effects but suffer from rapid clearance. CJC-1295 overcomes this by incorporating a maleimide-based DAC that anchors the peptide to endogenous albumin. The result is prolonged circulation and enhanced GH secretagogue activity while preserving natural pulsatility.

CJC-1295 DAC is described as a GHRH (Growth Hormone Releasing Hormone) analog that increases the creation and release of growth hormone. It’s presented as a modified version of MOD-GRF 1-29; the DAC (drug affinity complex) modification is noted for extending activity/half-life into the ~6–8 day range (rather than minutes).

Growth Hormone Studies

Preclinical evidence and hormone dynamics

Animal studies show that a single dose of CJC-1295 DAC can elevate GH levels two- to ten-fold, peaking roughly two hours post-administration and remaining elevated for up to six days. Importantly, the analogue preserves the natural pulsatile release of GH and downstream IGF-1.

In models with impaired GHRH physiology, CJC-1295 supports normal GH rhythms, pointing to potential roles in addressing growth deficits or dysregulated endocrine axes.

Fertility Research

Exploring reproductive applications

Historical research suggests that GHRH analogues can influence reproductive hormones. In female subjects, exogenous GH secretagogues have been shown to support ovulatory cycles, likely by boosting IGF-1 alongside GH. Early investigations also speculate on applications in male infertility through potential modulation of spermatogenesis, though dedicated studies are still needed.

Summary

Key takeaways and research considerations

CJC-1295 DAC is engineered for prolonged GH release without disrupting natural hormone rhythms. Moderate side effects and excellent subcutaneous bioavailability in murine models make it an attractive research peptide for endocrine, metabolic, and reproductive studies. As always, murine dose data do not translate directly to humans; the peptide remains restricted to licensed research use.

 

GHK-Cu is a natural peptide in human blood plasma, urine, and saliva. Research in animals reveals that GHK-Cu can improve wound healing, immune function, and skin health by stimulating collagen, fibroblasts and promoting blood vessel growth. There has been evidence that has shown that it acts as a feedback signal that is generated after tissue injury. It also suppresses free-radical damage and thus is an potent antioxidant

Naturally occurring copper tripeptide and its core properties

GHK-Cu is a naturally occurring peptide first isolated from human blood plasma and later identified in urine and saliva. Research highlights substantial benefits in wound healing and immune modulation. The short peptide exhibits anti-aging properties, suppresses free-radical damage, enhances protein synthesis, combats microbes, and supports the health of skin fibroblasts.

GHK-Cu is described as a naturally occurring copper peptide found in human plasma (with production noted to decrease with age). It’s commonly used in hair and skin products due to its described regenerative and anti-inflammatory properties, and is noted as influencing 500+ gene expressions associated with health and anti-aging benefits. (Educational / research context only.)

Deeper Research Notes (Summary):
• Described as affecting multiple pathways in the body, leading to a wide range of potential benefits.
• For tissue injuries, GHK-Cu is described as acting as a chemoattractant—supporting movement/signaling of cells during inflammatory actions—while releasing proteins associated with tissue growth and repair.
• Described as increasing collagen, supporting stem cell production, and contributing to bone formation by stimulating chondrocytes.
• Described as providing a copper source for cells, supporting angiogenesis (new blood vessel formation), which plays a role in tissue growth and survival.
• Described as blocking oxidative damage release from ferritin channels after injury, supporting enhanced regeneration for skin, hair follicles, stomach lining, bone tissue, fingernails, and other body tissues.

Research on GHK-Cu

Skin regeneration, antimicrobial action, and systemic support

GHK-Cu, a natural component of human blood, plays a crucial role in skin regeneration. Studies on skin cultures have revealed that GHK stimulates the production and breakdown of key skin components, including collagen, glycosaminoglycans, proteoglycans, and chondroitin sulfate. This effect is partially mediated by its ability to attract and coordinate the activity of fibroblasts, immune cells, and endothelial cells at the site of injury. GHK-Cu is commonly found in skincare and cosmetic products, where it enhances skin elasticity, tightens and firms the skin, reduces sun damage, hyperpigmentation, fine lines, and wrinkles. It also helps in scar reduction, prevents hypertrophic healing, smoothes rough skin, and rejuvenates aged skin, partly through its influence on transforming growth factor-Β and gene transcription.

Studies in mice have shown that GHK-Cu accelerates the healing process by up to 33% following burns, not only by recruiting immune cells and fibroblasts but also by promoting blood vessel growth, particularly crucial in burn wound care due to the cauterization effect.

GHK-Cu’s Antimicrobial Properties

The presence of foreign pathogens in tissues can significantly impede the wound healing process. Bacterial and fungal infections are particularly problematic in patients with burns or compromised immune systems, such as diabetes or HIV. GHK-Cu, in combination with specific fatty acids, forms a potent antimicrobial compound effective against various bacteria and fungi that often hinder wound healing. Research in diabetic patients has demonstrated that the addition of GHK-Cu to standard care regimens leads to a significant 40% increase in wound closure and a 27% reduction in infection rates compared to control groups. Similar benefits were observed in patients with ischemic open wounds.

GHK-Cu’s Impact on Cognition and Nervous System Function

The mechanisms behind neuron degeneration in conditions like Alzheimer’s remain poorly understood, posing challenges in developing effective treatments. However, studies suggest that GHK-Cu can counter the age-related decline in neuron function, a common factor in these diseases. GHK-Cu has been shown to enhance angiogenesis in the nervous system, promote nerve growth, and reduce inflammation in the central nervous system. There is even evidence indicating that GHK-Cu can reset abnormal gene expression and contribute to restoring a healthy state in dysfunctional systems.

GHK-Cu is naturally present in significant concentrations in the brain but declines with age. Scientists hypothesize that this decline in GHK-Cu may contribute to the vulnerability of nervous system tissues to natural insults, such as gene dysregulation, potentially playing a pivotal role in neurodegeneration, beyond the onset of new disease processes.

Research involving rodents suggests that GHK-Cu may safeguard brain tissue by inhibiting apoptosis, possibly through modulation of the miR-339-59/VEGFA pathway, a recognized pathway involved in brain injuries. GHK-Cu shows promise in ameliorating neurological deficits, reducing inflammation, and preventing neuron loss associated with excessive miR-339-5p expression[9].

GHK-Cu and Mitigating Chemotherapy Side Effects Studies in mice indicate that GHK-Cu has the potential to shield the lungs from fibrosis induced by the cancer drug bleomycin[10]. This could open the door to utilizing GHK-Cu as an adjunct to chemotherapy, permitting higher drug doses without a corresponding increase in adverse effects. Researchers have also identified a likely mechanism by which GHKC-Cu counters fibrosis, involving the regulation of TNF-alpha and IL-6 levels, both of which are inflammatory molecules affecting lung structure. By reducing lung inflammation, GHK-Cu averts fibrotic changes and enhances collagen deposition.

Similarly, GHK-Cu exhibits lung protection in mouse models of acute respiratory distress syndrome (ARDS), a swiftly progressing and potentially fatal lung condition linked to injuries, infections, and certain chemotherapy drugs. Once more, GHK-Cu appears to act by decreasing TNF-alpha and IL-6 expression[11].

GHK-Cu and Alleviating Pain In rat models, GHK-Cu administration displays a dose-dependent effect on pain-related behavior, potentially through elevating levels of the natural pain-relieving amino acid L-lysine[12]. Further studies also reveal GHK-Cu’s capacity to increase L-arginine levels, another pain-alleviating amino acid[13]. These findings open up new avenues for pain management, reducing reliance on addictive opiates and NSAIDs, which have been associated with cardiac side effects.

GHK-Cu demonstrates minimal side effects, strong oral and subcutaneous bioavailability in mice. However, dosage per kilogram in mice cannot be directly translated to humans. GHK-Cu, available from Peptide Sciences, is intended for educational and scientific research purposes only and is not for human consumption. It should only be purchased by licensed researchers.

 

Ipamorelin is a pentapeptide, composed of five amino acids. This compound acts as a GH secretagogue, functioning as an agonist that can bind to specific cell receptors and initiate cellular responses. In animal test subjects, Ipamorelin stimulates the pituitary gland to increase the secretion of growth-related substances while concurrently inhibiting the production of somatostatin, a secretion that suppresses growth. Moreover, Ipamorelin promotes the production of IGF-1 (Insulin-like Growth Factor 1), which plays a pivotal role in the growth and repair of muscular and skeletal tissues.

 

Introduction

Overview of Ipamorelin and its therapeutic properties

The Ipamorelin Peptide is gaining attention as a growth hormone secretagogue. In scientific research, it has shown promising potential in stimulating the production of growth hormones. This peptide may bring a myriad of potential benefits.

Ipamorelin is described as the mildest of GHRPs (Growth Hormone Releasing Peptides). It is discussed for stimulating growth hormone (GH) release without increasing appetite, cortisol, or prolactin.

Deeper Research Notes (Summary):
• Stimulates GH release by mimicking ghrelin, binding to GHS-R receptors in the brain, and inhibiting somatostatin (which suppresses GH production).
• Discussed as working on ghrelin receptors to promote GH release without increasing appetite (vs other GHRPs).
• GH support is discussed for muscle growth, fat metabolism, and bone health.
• Has shown potential for boosting insulin release from the pancreas (research discussion).

Research

Scientific studies on Ipamorelin and its therapeutic applications

Part 1. Ipamorelin Peptide: Overview and How It Works

Ipamorelin is a unique pentapeptide derived from GHRP-1, known for its selective release of growth hormone (GH) while leaving other hormone levels largely unaffected.

Part 2. Pharmacological Study of Ipamorelin Peptide

A comprehensive study has examined the pharmacological profile of Ipamorelin, revealing key insights into its behavior within the human body.

Significant increases in cortical BMC. Expanded femur and vertebra L6 volumes. Increased body weight, cortical bone area, and BMC. Notable improvements in dry defatted weight and bone volume after 12 weeks.

2. Ipamorelin Stimulates Longitudinal Bone Growth in Rats

Ipamorelin positively influenced longitudinal bone growth rate (LGR) and body weight (BW) in rats.

Key findings include:

A shorter median time to the first tolerated meal in the Ipamorelin group, Similar safety and efficacy profiles between Ipamorelin and placebo groups.

Possible side effects may include:

Fluid retention, joint pain, headaches, increased appetite, heightened response to insulin, affecting blood sugar levels.

Ipamorelin is a growth hormone secretagogue. It has selective and potential benefits in bone growth and postoperative ileus management. While some potential side effects have been suggested, further comprehensive research is needed to understand its safety and efficacy fully.

 

The Mitochondrial-Derived Peptide MOTS-c enhances metabolic balance and longevity. It enhances exercise performance, lowers obesity, mitigates insulin resistance, and addresses conditions like osteoporosis.

MOTS-c Overview

Introduction to mitochondrial-derived peptides and MOTS-c

MOTS-c is a short peptide encoded in the mitochondrial genome and is part of the mitochondrial-derived peptides (MDPs) group. Recent discoveries have revealed that MDPs act as bioactive hormones involved in mitochondrial communication and energy regulation. Initially associated solely with mitochondria, further research has unveiled their presence in the cell nucleus and their circulation in the bloodstream, exerting systemic effects. MOTS-c, a newly identified MDP, has demonstrated its significance in metabolism, weight regulation, exercise capacity, longevity, and processes leading to diseases like osteoporosis. It has been detected both in cell nuclei and in the general circulation, establishing its status as a natural hormone. In the past five years, MOTS-c has garnered significant attention in the field of research due to its therapeutic potential.

MOTS-C is produced from a gene in mitochondrial DNA and belongs to a group called mitochondrial-derived peptides (MDPs). It’s described as being able to enter the cell nucleus and circulate in the bloodstream, with ongoing research exploring its potential impact on metabolism, weight management, exercise capacity, and longevity.

Deeper Research Notes (Summary):
• MOTS-C is described as mainly acting on the AICAR pathway, which activates the AMPK pathway—associated with regulation of energy metabolism, improved insulin sensitivity, reduced inflammatory responses, enhanced fatty tissue activation, exercise-induced benefits, and anti-aging protection.
• It’s described as improving muscle function by enhancing glucose uptake, and boosting brown fat activity to support calorie burning and fat reduction.
• It’s also described as supporting bone health by enhancing the survival and function of osteoblasts (bone-building cells).
• MOTS-C is described as supporting endothelial cell function to improve circulation, with potential downstream implications for heart health and reduced heart-related risk.

 

Muscle Metabolism

Effects on glucose uptake and muscle function

 

 

Research in mice suggests that MOTS-c can reverse age-related insulin resistance in muscles, enhancing glucose uptake by skeletal muscles. This effect is achieved by improving the response of skeletal muscles to AMPK activation, leading to increased expression of glucose transporters. Notably, this mechanism operates independently of the insulin pathway, providing an alternative method for boosting glucose uptake in muscles when insulin is insufficient. The overall outcome is improved muscle function, enhanced muscle growth, and reduced functional insulin resistance.

 

Fat Metabolism

Impact on adipose tissue and metabolic regulation

Studies in mice have indicated that low estrogen levels can lead to increased fat accumulation and abnormal adipose tissue function, elevating the risk of insulin resistance and diabetes. Supplementing mice with MOTS-c, however, enhances brown fat function and reduces adipose tissue accumulation. Additionally, MOTS-c appears to prevent adipose tissue dysfunction and inflammation, which are often precursors to insulin resistance.

MOTS-c's influence on fat metabolism is partially mediated through the activation of the AMPK pathway, a well-established pathway that promotes the uptake and metabolism of both glucose and fatty acids in cells during periods of low energy levels. This pathway is also activated by ketogenic diets, such as the Atkins diet, which encourage fat metabolism while preserving lean body mass.

Recent research suggests that MOTS-c can translocate from mitochondria to the nucleus, where it can affect the expression of nuclear genes. After metabolic stress, MOTS-c has been shown to regulate nuclear genes involved in glucose regulation and antioxidant responses.

Evidence from studies in mice suggests that MOTS-c, particularly in the context of obesity, plays a crucial role in regulating sphingolipid, monoacylglycerol, and dicarboxylate metabolism. By downregulating these pathways and increasing beta-oxidation, MOTS-c appears to prevent the accumulation of fat. Some of these effects are likely mediated through MOTS-c's actions in the nucleus. Research on MOTS-c has given rise to a new hypothesis concerning fat deposition and insulin resistance, offering potential insights into the pathophysiology of obesity and diabetes. Dysregulation of fat metabolism in mitochondria may lead to reduced fat oxidation, prompting elevated insulin levels in an attempt to clear lipids from the bloodstream, ultimately resulting in increased fat deposition and insulin resistance.

Supplementation of MOTS-c in rats has been shown to prevent mitochondrial dysfunction and fat accumulation, even in the presence of a high-fat diet.

Insulin Sensitivity

Role in diabetes prevention and metabolic health

Research assessing MOTS-c levels in individuals with varying insulin sensitivity has revealed that the protein is associated with insulin sensitivity primarily in lean individuals. This suggests that MOTS-c may play a role in the development of insulin insensitivity rather than its maintenance. Scientists speculate that monitoring MOTS-c levels in lean, pre-diabetic individuals could serve as an early indicator of potential insulin resistance. Supplementation with MOTS-c in this population may help delay the onset of insulin resistance and the development of diabetes. Although promising results have been observed in mouse studies, further research is required to fully understand MOTS-c's impact on insulin regulation.

Osteoporosis

Effects on bone formation and osteoblast function

MOTS-c appears to be involved in the synthesis of type I collagen by osteoblasts in bone. Research in osteoblast cell lines suggests that MOTS-c regulates the TGF-beta/SMAD pathway, which is responsible for osteoblast health and survival. By promoting osteoblast survival, MOTS-c enhances the synthesis of type I collagen, consequently improving bone strength and integrity.

Further research in osteoporosis has shown that MOTS-c promotes the differentiation of bone marrow stem cells through the same TGF-beta/SMAD pathway, leading to increased osteogenesis (formation of new bone). Thus, MOTS-c not only protects osteoblasts and supports their survival but also promotes their development from stem cells.

Longevity and Heart Health

Cardiovascular benefits and aging research

Studies on MOTS-c have identified a specific genetic variation in the peptide associated with longevity in certain populations, such as the Japanese. This genetic change involves substituting a glutamate residue for the lysine normally found at position 14 of the protein. While the functional implications of this change are not yet fully understood, it is exclusive to individuals of Northeast Asian ancestry and is believed to contribute to their exceptional longevity.

According to Dr. Changhan David Lee, a researcher at the School of Gerontology at USC Leonard Davis, mitochondria are crucial for extending both lifespan and healthspan in humans. Mitochondria are strongly implicated in aging and age-related diseases. Previously, dietary restriction was the primary method to influence mitochondrial function and longevity. Peptides like MOTS-c, however, may offer a more direct way to impact mitochondrial function.

Research involving patients undergoing coronary angiography has revealed that individuals with lower levels of MOTS-c in their blood exhibit higher levels of endothelial cell dysfunction. Endothelial cells, lining the interior of blood vessels, play a crucial role in regulating blood pressure, blood clotting, and plaque formation. Studies in rats suggest that while MOTS-c doesn't directly affect blood vessel responsiveness, it does sensitize endothelial cells to the effects of other signaling molecules, like acetylcholine. Supplementation with MOTS-c has been shown to enhance endothelial function and improve the function of microvascular and epicardial blood vessels.

MOTS-c is not the only mitochondria-derived peptide (MDP) affecting heart health. Research suggests that at least three MDPs play roles in protecting cardiac cells from stress and inflammation, potentially playing a role in cardiovascular disease development and reperfusion injury.

MOTS-c has demonstrated minimal side effects, low oral availability, and excellent subcutaneous bioavailability in mice. However, the dosage in mice does not scale directly to humans. MOTS-c available for purchase at Peptide Sciences is intended for educational and scientific research purposes only and is not for human consumption. It should only be obtained by licensed researchers.

 

Thymosin Beta-4, consisting of a 43 amino acid peptide sequence, has demonstrated its potential in animal models for various beneficial effects. These include the enhancement of blood vessel growth, the regulation of wound healing processes, the reduction of inflammation, and the mitigation of oxidative damage in vital areas such as the heart and central nervous system. Thymosin Beta-4 plays a significant role in safeguarding tissues, facilitating repair, promoting tissue regeneration, and aiding in the restructuring of injured or damaged tissues. It is also a subject of active research interest in the field of anti-aging, given its potential to support longevity and overall health.

 

Introduction

Thymosin Beta 4, also known as TB-500, is a synthetic version of a naturally occurring 43-amino acid peptide found in a wide range of human and animal cells. Research, such as a 2010 study published in the Annals of the New York Academy of Sciences, has indicated the potential of TB-500 in facilitating the repair of cardiac muscle after injuries like myocardial infarction (heart attack). TB-500 was found to be promising in cases where stem cell therapy had limitations. It demonstrated the ability to inhibit the death of myocardial cells, stimulate the growth of blood vessels, and activate processes within the heart that promote healing following injury. This suggests that TB-500 could be a groundbreaking agent for actively restoring damaged cardiac muscle after a heart attack. Previous studies in mice conducted in 2004 also supported the idea of TB-500 promoting cardiomyocyte migration, survival, and repair of myocardial damage.

Research on TB-500

Several studies have explored the potential benefits of Thymosin Beta 4 (TB-500) across various health conditions: Diabetic Eye Surgery: A 2009 study utilizing TB-500 eye drops at a concentration of 0.01% demonstrated accelerated healing following eye surgery in diabetic patients, who often face complications in healing, particularly with diabetic retinopathy. The study indicated no serious side effects, though some patients reported mild issues like headache, dizziness, and insomnia.

Cystic Fibrosis and Mucociliary Transport: TB-500 was studied in cystic fibrosis patients and, when combined with dornase alfa, resulted in a significant reduction in sputum cohesivity. This combination therapy improved mucociliary transport of mucus and cough transport in these patients.

Liver Disease: TB-500 was investigated in the context of chronic hepatitis B combined with nonalcoholic fatty liver disease (NAFLD). Although it did not directly correlate with HepB Virus levels or liver function tests, it showed a negative correlation with inflammation and fibrosis scores, suggesting potential benefits in certain liver diseases.

Safety and Tolerance: A human safety and tolerance study conducted in 2010 found that intravenous (IV) doses of TB-500 ranging from 42mg to 1260mg daily for 14 days had no treatment-related adverse effects or dose-related toxicity.

Immune Response and Respiratory Virus: A study involving healthy volunteers exposed to rhinovirus (common cold virus) found an increase in serum cortisol, thymosin alpha 1, and TB-500 on the fifth day post-exposure. This correlated with an increase in various immune cells, indicating a cooperative effect between thymosin and the immune response to respiratory viruses.

Kidney Disease: Research in mice with and without kidney disease revealed that low levels of natural TB-500 were associated with accelerated kidney disease progression. This suggests that endogenous TB-500 levels play a protective role in kidney health.

Skin and Wound Healing: TB-500 has shown promise in accelerating the healing of skin in various conditions, including burns, diabetic ulcers, pressure ulcers, and more. It enhances angiogenesis, exhibits anti-inflammatory properties, and increases platelet aggregation at wound sites.

Meta-Analysis: A 2015 meta-analysis of studies on TB-500 highlighted its potential in a wide range of disease processes, including tissue regeneration, heart repair after heart attacks, brain healing post-stroke and trauma, improvements in kidney and liver diseases, spinal cord and bone injuries, and mitigating the effects of aging and viral infections.

Fracture Healing: TB-500 treatment in mice with fractures led to significantly improved strength and stiffness in healed fractures compared to untreated mice. Imaging also revealed better-healed injury sites.

Spinal Cord Injury: In a study involving rats with spinal cord injuries, TB-500 administration led to marked improvements in locomotor and behavioral assessments, reduced inflammatory cytokines, scar size, and increased levels of myelin proteins, suggesting potential benefits for humans with spinal cord injuries.

Traumatic Brain Injury (TBI): TB-500 has been shown to have neuroprotective and neurorestorative effects in rat models of traumatic brain injury. It promotes increased blood flow, the generation of new brain cells, and the formation of new connections between brain cells.

Multiple Sclerosis (MS): In rat models, TB-500 administration increased the number of newly generated oligodendrocytes, reduced axonal damage, and promoted remyelination of axons, correlating with functional improvement in multiple sclerosis. These studies collectively suggest that TB-500 may hold promise in various medical applications and therapeutic interventions for a wide range of health conditions. However, further research, including clinical trials in humans, is needed to fully understand its potential and safety.